Article Abstract

Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib

Authors: You-Cai Zhu, Wen-Xian Wang, Chun-Wei Xu, Qing-He Tan, Jian-Ying Li, Wu Zhuang, Zheng-Bo Song, Kai-Qi Du, Gang Chen, Tang-Feng Lv, Yong Song


Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related morbidity and mortality worldwide (1). Epidermal growth factor receptor (EGFR) mutations, as driver oncogenes, were first identified in NSCLC in 2004 (2).